Wall Street analysts have concluded Amgen’s $13.4 billion purchase of psoriasis drug Otezla represents an overpayment of at least $2 billion. But with its Enbrel sales force, Amgen may be equipped to make the deal a success, they add. More:
read moreAstraZeneca and GlaxoSmithKline have long locked horns in their battle for respiratory supremacy with the latter holding the clear advantage in triple-drug inhaler market. Another round of positive data for its combo candidate could give AZ a leg up. More:
read moreGSK is now responsible for all development, regulatory and commercialisation activities and costs. More: Ionis to license hep B programme to GSK Source: News
read moreBreztri Aerosphere – formerly known as PT010 – showed a 52% reduction in exacerbations. More: AZ’ triple combo hits endpoint in COPD trial Source: News
read moreThe clinical management of hypertension accounts for 12% of visits to primary care and up to £2.1 billion of healthcare expenditure. More: NICE updates hypertension guideline Source: News
read moreThe approval is based on data from the ELOQUENT-3 trial. More: Empliciti combo bags EU approval for multiple myeloma Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals